Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Using Antibody Therapeutics to Block Allergic Reactions with Dr. Jessica Grossman IgGenix TRANSCRIPT
Download PDFAug 22, 2022
Dr. Jessica Grossman is the CEO of an early stage biotech, IgGenix, the world leader in discovering and characterizing IgE antibodies which have been identified as the cause of allergies. With an initial focus on peanut allergy, IgGenix is developing a plan to use a subcutaneous injection to block specific allergic reactions immediately.
Jessica explains, "At IgGenix, what we do is start with whole blood donations from allergic donors. And we take that blood and isolate out the single B cells that are making the IgE antibodies. We get those IgE antibodies, and we transform them into an IgG antibody that's actually protective. And I'll use again, peanut as an example. That's our lead program, which we're the furthest ahead. We have done some pre-clinical work, some animal studies, which look remarkably promising, and I'm excited about it. But what we envision our therapy looking like is an antibody therapeutic that would be given to an individual, and the antibody would immediately protect them from any accidental exposure."
"So we isolate these very rare B cells that produce IgE antibodies, and they're about 0.05% of the circulating blood cells. Because the IgE antibodies are so rare, they're also extremely potent, meaning they have a very high affinity. And when you are allergic, they seek out the food that you're allergic to and cause this immediate reaction. What we're doing is taking those very potent IgE antibodies, converting them to IgG antibodies to act as blockers."
#IgGenix #FoodAllergyResearch #AllergicDisease #BCells #AntibodyTherapeutics #AirborneAllergies #EnvironmentalAllergies #SustainableInnovation #WomenInSTEM #Biotech
